Health
COVID-19: NAFDAC Approves Production Of Chloroquine For Clinical Trial
The National Agency for Food and Drug Administration and Control, NAFDAC, has approved the production of Chloroquine for clinical trials in an effort to find a cure for Coronavirus.
This is coming after the President of the United State of America, Donald Trump, approved the use of Chloroquine for COVID-19 patients.
The development was revealed by the Director-General of the agency, Mojisola Adeyeye, during an announcement on Friday at the NAFDAC headquarters in Lagos.
She, however, noted that NAFDAC is not approving Chloroquine for the treatment of COVID-19 but for clinical trials to find a cure for the virus.
“NAFDAC is not approving Chloroquine as a product that has can be used for Coronavirus because there is no submission to us for registration but because it is under clinical trials, NAFDAC approves medicines meant for clinical trials.”
“Therefore the medicine is being approved just for the clinical trials,” Adeyeye said.
She charged individuals that are interested in doing a clinical trial on Chloroquine to approach approved outlets.
“Right now, we have asked one company to make a batch of Chloroquine for the purpose of a clinical trial,” Adeyeye added.
